Drug Profile
RPH 203
Alternative Names: RPH-203Latest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator R-Pharm
- Class Antineoplastics; Recombinant fusion proteins
- Mechanism of Action RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bone cancer; Osteoporosis
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for phase-I development in Bone-cancer(In volunteers) in Australia (Parenteral)
- 28 Jan 2018 No recent reports of development identified for phase-I development in Osteoporosis(In volunteers) in Australia (Parenteral)
- 31 May 2013 Preclinical trials in Bone cancer in Australia (Parenteral)